Target intelligence / Profile preview

Bacterial beta-glucosidases TmGH1 and TxGH116 (TmGH1 and TxGH116)

Target
TmGH1 and TxGH116
Molecular classification
Enzyme, Glycoside hydrolase, Beta-glucosidase
01

Overview

Bacterial beta-glucosidases TmGH1 (from Thermotoga maritima) and TxGH116 (from Thermoanaerobacterium xylanolyticum) are highly stable enzymes belonging to the glycoside hydrolase families 1 and 116, respectively. In nature, these enzymes facilitate the breakdown of complex polysaccharides into glucose, playing a critical role in bacterial energy metabolism and biomass degradation. In a biomedical context, they serve as essential structural and functional surrogates for human enzymes; TmGH1 is a model for the lysosomal acid beta-glucosidase (GBA1), while TxGH116 is a model for the non-lysosomal beta-glucosidase (GBA2). These bacterial homologs are frequently utilized in drug discovery to screen for pharmacological chaperones and inhibitors aimed at treating Gaucher disease and associated neurodegenerative disorders like Parkinson's disease. Their robust stability and ease of crystallization allow researchers to map the binding modes of small molecules, providing insights into the catalytic mechanisms and inhibitory pathways relevant to human health.

Other names
Thermotoga maritima beta-glucosidase (TmGH1)Thermoanaerobacterium xylanolyticum beta-glucosidase (TxGH116)Glycoside hydrolase family 1 beta-glucosidaseGlycoside hydrolase family 116 beta-glucosidaseBacterial GBA1 and GBA2 homologs
02

Mechanism of action

These enzymes are targeted by competitive inhibitors and mechanism-based covalent inactivators that mimic the transition state of glucoside hydrolysis, thereby blocking the active site and preventing substrate processing.

03

Biological functions

Carbohydrate metabolismHydrolysis of terminal, non-reducing beta-D-glucosyl residuesCellulose degradationBiomass conversion
04

Disease associations

Gaucher disease (as structural models for human GBA1 and GBA2)Parkinson's disease (as structural models for GBA-related pathology)Bacterial infection (potential antimicrobial target in specific pathogens)
05

Safety considerations

Off-target inhibition of human glycosidasesPotential for gastrointestinal distress if used in vivo due to inhibition of digestive enzymesSpecies-specific differences in inhibitor binding
06

Interacting drugs

Isofagomine

4 more in the full profile.

07

Biomarkers

Enzyme activity levelsGlucosylceramide accumulation (in model systems)

Beyond the preview

Go deeper on Bacterial beta-glucosidases TmGH1 and TxGH116 (TmGH1 and TxGH116).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial beta-glucosidases TmGH1 and TxGH116 (TmGH1 and TxGH116).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call